Latest updates for Merck

Fresh curated links around Merck are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Recent items include:

  • Merck: Navigating the Patent Cliff and Future Growth Prospects
  • Merck’s anti-TL1A antibody from Prometheus buyout passes ph. 3 test in ulcerative colitis
  • Merck launches GCC in Bengaluru

Post angles to try

Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

fool.com /1 month ago

Merck: Navigating the Patent Cliff and Future Growth Prospects

Join us as we dissect Merck's stock potential and the challenges it faces with the impending patent cliff of Keytruda. Can this pharmaceutical giant maintain its edge in the market...

Read source
fiercebiotech.com /3 weeks ago

Merck’s anti-TL1A antibody from Prometheus buyout passes ph. 3 test in ulcerative colitis

Merck is making advances in the lucrative ulcerative colitis field with the key prize of its $11 billion buyout from several years ago.

Read source
thehindubusinessline.com /2 weeks ago

Merck launches GCC in Bengaluru

Merck’s Bengaluru GCC to bring together approximately 3,300 professionals

Read source
biopharmadive.com /1 month ago

At ASCO, Merck makes case for a ‘cornerstone’ cancer drug

Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.

Read source
koreatimes.co.kr /2 weeks ago

[PHOTO] Celebrating 40th anniv.

Merck Korea Managing Director Kim Woo-kyu, fourth from left, cuts cake to celebrate the 40th anniversary of the company's Ansan production site during a ceremony at the plant in Gy...

Read source
roi-nj.com /1 month ago

Merck Animal Health announces acquisition of TARGAN

Rahway-based Merck Animal Health, a division of Merck & Co., Inc., announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developi...

Read source
fiercebiotech.com /3 weeks ago

Merck KGaA pledges $50M to build new cardio biotech with eye to later acquisition

Merck KGaA has committed $50 million to build a new biotech with prolific life science investor Versant Ventures, with the ultimate goal of devouring the NewCo down the line.

Read source
seekingalpha.com /1 month ago

Merck & Co., Inc. (MRK) Discusses Oncology Strategy and Program Update With Focus on Clinical Progress and Pipeline...

Read source
seekingalpha.com /1 month ago

Merck & Co., Inc. (MRK) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Read source
biopharmadive.com /1 month ago

Merck ADC, licensed from China, hits mark in first big global trial

The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next deca...

Read source
zootecnicainternational.com /1 month ago

TARGAN announces sale to Merck Animal Health

Raleigh, North Carolina, United States, June 11, 2026 — TARGAN Inc, a privately held innovator in developing and commercializing biodevice solutions to improve performance outcomes...

Read source
fiercebiotech.com /1 month ago

Merck inks $510M biobucks data generation partnership with Protillion

AI drug design specialist Protillion has inked a $510 million biobucks collaboration and license agreement with Merck & Co. that brings together Protillion’s platform and Merck...

Read source
pharmexec.com /4 weeks ago

<![CDATA[Pharma M&A Roundup: Protillion Biosciences Enters Drug Discovery Collaboration with Merck, Jazz Pharmace...

Read source
pharmexec.com /1 week ago

<![CDATA[Novartis to Acquire Myricx Bio for $1.1 Billion]]>

Read source
cafepharma.com /4 weeks ago

Merck Laying Me Off Did Me A Favor

Merck Laying Me Off Did Me A Favor Anonymous (not verified) Wed, 06/17/2026 - 23:57 field_thread_url https://cafepharma.com/boards/threads/merck-laying-me-...

Read source
cafepharma.com /2 weeks ago

Merck Laying Me Off Did Me A Favor

Merck Laying Me Off Did Me A Favor Anonymous (not verified) Sun, 06/28/2026 - 03:03 field_thread_url https://cafepharma.com/boards/threads/merck-laying-me-...

Read source
fiercebiotech.com /3 days ago

Merck KGaA institutes in-office requirement for US research team that could lead to 70 layoffs

Merck KGaA’s U.S. research site has instituted a new in-office work requirement that may lead to the imminent departure of as many as 70 staffers.

Read source
fiercebiotech.com /2 weeks ago

Merck halts ph. 2 Alzheimer’s trial after Neuphoria small molecule underwhelms

Merck & Co. has nixed the phase 2 study of a potential Alzheimer’s disease medicine after the drug underwhelmed in an interim analysis, marking another blow for the pharma’s st...

Read source
seekingalpha.com /1 month ago

Merck KGaA (MKKGY) Presents at DbAccess European Champions Conference 2026 - Slideshow

Read source
biopharmadive.com /2 weeks ago

FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services

Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brough...

Read source
pharmexec.com /1 week ago

<![CDATA[Pharma M&A Roundup: Chemomab Therapeutics Enters Merger Agreement with Scipher Medicine, Teva and Polpha...

Read source
pharmexec.com /1 month ago

<![CDATA[Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio]]>

Read source
biopharmadive.com /22 hours ago

Merck ADC, in China study, shows potential to replace chemo in lung cancer

The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for fro...

Read source
pharmexec.com /1 month ago

<![CDATA[Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Joh...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.

Sources covering Merck

seekingalpha.com

Recent coverage from public sources
Public source

cafepharma.com

Recent coverage from public sources
Public source

seekingalpha.com

Recent coverage from public sources
Public source

biopharmadive.com

Recent coverage from public sources
Public source

fiercebiotech.com

Recent coverage from public sources
Public source

fool.com

Recent coverage from public sources
Public source